[Image courtesy of PubChem]
Proponents of ketamine for depression describe its remarkable ability to catalyze improvements in many patients’ mood disorders such as depression and anxiety.However, the question of how the dissociative anesthetic ketamine should be used in the long-term to manage mood order symptoms is less clear.
Pharma efforts in ketamine for depressionFirst synthesized in 1962, ketamine’s patent expired in 2002. Janssen, however, managed to secure patent protection for Spravato, the S-enantiomer of ketamine that won FDA approval in 2019.
Janssen has not disclosed sales figures for its nasal spray-based Spravato, but GlobalData projects it will generate global sales of roughly $383 million by 2029.
Seelos Therapeutics, is developing intranasal racemic ketamine for acute suicidal ideation and behavior in patients with major depressive disorder (MDD). The company …